磷脂化重组人铜锌超氧化物歧化酶(Beijing Tide Pharmaceutical)(PC-SOD) - 药物靶点：SOD1_在研适应症：心肌再灌注损伤_专利_临床

概要

基本信息

药物类型

酶

别名

CY

靶点

SOD1

作用方式

调节剂

作用机制

SOD1调节剂(超氧化物歧化酶调节剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构-

权益机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)临床2期

特殊审评-

登录后查看时间轴

关联

7

项与磷脂化重组人铜锌超氧化物歧化酶(Beijing Tide Pharmaceutical) 相关的临床试验

JPRN-jRCT2031210466

/ Completed临床2期IIT

Placebo-controlled, double-blind, randomized phase II study of PC-SOD for chemotherapy-induced peripheral neuropathy

开始日期2022-01-19

申办/合作机构-

NCT03995732

/ Unknown status临床2期

Efficacy and Safety Evaluation of Phosphatidyl Choline Cu/Zn Superoxide Dismutase (PC-SOD) for Injection in Reducing Myocardial Reperfusion Injury: a Multicenter, Randomized, Single-blind, Placebo-controlled Dose-finding Study

The current study aims to evaluate different doses of PC-SOD injections for efficacy and safety in comparison to placebo, in order to provide a basis for future clinical trials in terms of experimental design and dose selection.

开始日期2019-06-18

申办/合作机构

北京泰德制药股份有限公司

[+1]

CTR20160765

/ Completed临床1期

CY单中心、随机双盲、安慰剂平行对照、剂量递增单次静脉给药健康志愿者耐受性及药代动力学临床试验

评价CY在健康成年志愿者中，单次静脉推注给药的耐受性和药代动力学行为。

开始日期2016-12-19

申办/合作机构

北京泰德制药股份有限公司

100 项与磷脂化重组人铜锌超氧化物歧化酶(Beijing Tide Pharmaceutical) 相关的临床结果

登录后查看更多信息

100 项与磷脂化重组人铜锌超氧化物歧化酶(Beijing Tide Pharmaceutical) 相关的转化医学

登录后查看更多信息

100 项与磷脂化重组人铜锌超氧化物歧化酶(Beijing Tide Pharmaceutical) 相关的专利（医药）

登录后查看更多信息

41

项与磷脂化重组人铜锌超氧化物歧化酶(Beijing Tide Pharmaceutical) 相关的文献（医药）

2022-01-01·Life Sciences3区 · 医学

Novel pharmacological effects of lecithinized superoxide dismutase on ischemia/reperfusion injury in the kidneys of mice

3区 · 医学

Article

作者: Shimoda, Mikako ; Kawahara, Masahiro ; Mizushima, Tohru ; Takafuji, Ayaka ; Kubota, Maho ; Tanaka, Ken-Ichiro

Renal ischemia/reperfusion (I/R) injury is a major clinical problem because it can cause acute kidney injury (AKI) or lead to the transition from AKI to chronic kidney disease (CKD). Oxidative stress, which involves the production of reactive oxygen species (ROS), plays an important role in the development and exacerbation of I/R-induced kidney injury. However, we have previously reported that lecithinized superoxide dismutase (PC-SOD), a SOD derivative with high tissue affinity and high stability in plasma, has beneficial effects in various disease models because of its inhibitory effect on ROS production. Therefore, we aimed to determine the effects of intravenous PC-SOD administration in a mouse model of renal injury induced by I/R. PC-SOD markedly ameliorated the I/R-induced increases in markers of renal damage (urea nitrogen, creatinine, neutrophil gelatinase-associated lipocalin, and interleukin-6) and tubular necrosis 48 h after the intervention. We also found that PC-SOD significantly ameliorated the I/R-induced increase in ROS production, using an ex vivo imaging system. Furthermore, PC-SOD inhibited the increases in expression of markers of fibrosis (α-smooth muscle actin and collagen 1A1) 96 h after, and renal fibrosis 25 days after I/R was induced. Finally, we found that PC-SOD ameliorated the I/R-induced AKI in mice with high-fat diet-induced prediabetes. These results suggest that PC-SOD inhibits AKI and the transition from AKI to CKD through the inhibition of ROS production. Therefore, we believe that PC-SOD may represent an effective therapeutic agent for I/R-induced renal injury.

2021-09-01·Biomedicine & Pharmacotherapy2区 · 医学

Lecithinized superoxide dismutase in the past and in the present: Any role in the actual pandemia of COVID-19?

2区 · 医学

Review

作者: Farella, Ilaria ; Panza, Raffaella ; Laforgia, Nicola ; Capozza, Manuela

The Coronavirus disease 19 (Covid-19) pandemic is devastating the public health: it is urgent to find a viable therapy to reduce the multiorgan damage of the disease. A validated therapeutic protocol is still missing. The most severe forms of the disease are related to an exaggerated inflammatory response. The pivotal role of reactive oxygen species (ROS) in the amplification of inflammation makes the antioxidants a potential therapy, but clinical trials are needed. The lecitinized superoxide dismutase (PC-SOD) could represent a possibility because of bioaviability, safety, and its modulatory effect on the innate immune response in reducing the harmful consequences of oxidative stress. In this review we summarize the evidence on lecitinized superoxide dismutase in animal and human studies, to highlight the rationale for using the PC-SOD to treat COVID-19.

2019-12-01·Int. Journal of Clinical Pharmacology and Therapeutics4区 · 医学

Pharmacokinetics and safety of PC-SOD, a lecithinized recombinant superoxide dismutase, in healthy Chinese subjects: A phase 1, randomized, placebo-controlled, dose-escalation study

4区 · 医学

Article

作者: Zhao, Qian ; Jin, Xin ; Zhu, Zhenyu ; Wu, Ni ; Liu, Chunyan ; Chen, Rui ; Zhong, Wen ; Hu, Pei

OBJECTIVESTo evaluate the pharmacokinetics of PC-SOD after single intravenous administration and its safety profile in healthy Chinese subjects.MATERIALS AND METHODSThis was a phase 1, randomized, double-blind, placebo-controlled, sequential, single-dose, and dose-escalation study. The study was done in 4 cohorts and a total of 40 subjects received a single dose of PC-SOD (from 20 to 160 mg). There were 12 subjects in each dose group (10 active treatments and 2 placebos), except a 20-mg group, in which all 4 subjects were given active treatment. Serial venous blood samples were collected up to 168 hours after dosing. Serum samples were analyzed using an enzyme-linked immunosorbent assay. Pharmacokinetic parameters of PC-SOD were calculated via noncompartmental analysis using the WinNonlin.RESULTSAfter intravenous administration, PC-SOD reached the peak concentration quickly with a median t_max of 0.5 - 1.3 hours across all dose cohorts. After reaching C_max, the mean T_1/2 was 35.9 - 42.3 hours, which was independent of dose. The CL and V_z were 0.13 L/h and 6.72 L, 0.13 L/h and 7.33 L, and 0.11 L/h and 6.88 L for the 40, 80, and 160 mg dose cohorts, respectively. Over the dose range of 20 - 160 mg, the mean C_max increased from 5,546.6 to 44,145.2 h×ng/mL and AUC_last increased from 117,464.5 to 1,348,209.4 h×ng/mL. The 90% CI for β of AUC or C_max slightly exceeded the criterion, indicating that there was approximate dose proportionality over the range of 20 - 160 mg or 40 - 160 mg of PC-SOD. Generally, PC-SOD was well tolerated in doses up to 160 mg in healthy Chinese subjects. Reversible elevated blood triglyceride levels were reported in 2 subjects as moderate adverse events, and all other reported adverse events were considered to be mild. The possibility of a drug hypersensitivity syndrome was not high for PC-SOD in Chinese subjects based on current data.CONCLUSIONSingle intravenous administrations of PC-SOD in doses up to 160 mg were well tolerated in healthy Chinese subjects. The prolonged half-life of PC-SOD was confirmed and independent of dose. Over the range of 20 - 160 mg, PC-SOD showed approximate dose proportionality. These findings suggest that it is worthwhile to investigate PC-SOD in clinical conditions characterized by a high radical overload.

100 项与磷脂化重组人铜锌超氧化物歧化酶(Beijing Tide Pharmaceutical) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
心肌再灌注损伤	临床2期	中国	北京泰德制药股份有限公司	2019-05-23
心肌梗塞	临床前	中国	北京泰德制药股份有限公司	2016-12-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EHA2023	N/A	血液肿瘤	85	Intermediate-dose AraC+G-CSF	夢壓窪願鏇鏇窪積鏇簾(鏇構膚簾獵夢襯製襯窪) = 艱蓋鹹窪構壓範齋膚襯選選糧簾繭醖構鏇鬱膚 (鹹膚淵糧夢鏇鑰遞鹽齋 )	-	2023-06-08
				Cy+G-CSF	夢壓窪願鏇鏇窪積鏇簾(鏇構膚簾獵夢襯製襯窪) = 鹹鑰糧膚積網構衊積簾選選糧簾繭醖構鏇鬱膚 (鹹膚淵糧夢鏇鑰遞鹽齋 )
P552 (EBMT2022)	N/A	多发性骨髓瘤	156	24 hours continuous infusion of Cy	(餘繭壓齋衊選醖醖膚積) = 鏇蓋簾膚鹽憲遞顧醖鑰夢餘選衊選襯窪顧鏇遞 (襯餘壓獵窪鹹選窪鹽蓋 ) 更多	-	2022-03-19
				short time (4-6 hours) infusion of Cy	(餘繭壓齋衊選醖醖膚積) = 糧鹹憲簾鬱範鹽蓋積觸夢餘選衊選襯窪顧鏇遞 (襯餘壓獵窪鹹選窪鹽蓋 ) 更多
ASCT1201 (EHA2020)	临床2期	多发性骨髓瘤巩固 \| 维持	54	CBD regimen	簾顧鹽構衊壓廠蓋鑰鏇(積繭襯醖廠艱鬱鑰鏇製) = 鑰淵艱鬱鏇鏇願鹹窪夢範壓鹽遞壓繭鹽齋醖齋 (製餘簾選鑰艱鹹製鹽夢, 42.5%>69.3%) 更多	-	2020-05-14
				CY and VAD regimen	簾顧鹽構衊壓廠蓋鑰鏇(積繭襯醖廠艱鬱鑰鏇製) = 鹽衊鹹鹹糧獵襯鏇觸淵範壓鹽遞壓繭鹽齋醖齋 (製餘簾選鑰艱鹹製鹽夢 ) 更多
ASCO2014	N/A	多发性骨髓瘤	24	TBI8/CY	(簾遞醖鬱築鑰鏇醖遞觸) = 遞齋艱鑰製襯襯壓蓋餘遞廠鹹淵壓網鑰願蓋餘 (襯鏇膚壓鑰廠簾蓋繭艱 ) 更多	-	2014-05-20
Tandem Meetings ASTCT and CIBMTR2010	N/A	多发性骨髓瘤	72	Cy 4gm/m2+G-CSF	壓衊鑰廠壓夢壓範簾夢(範餘艱廠壓繭繭範淵繭) = 築築醖製積築窪遞鹹淵獵網構艱醖膚鹽積窪顧 (鏇蓋鹽築廠鏇鹹壓夢願 ) 更多	不佳	2010-02-01
				Cy 2gm/m2+G-CSF	壓衊鑰廠壓夢壓範簾夢(範餘艱廠壓繭繭範淵繭) = 膚繭夢鹽窪鏇顧構鏇齋獵網構艱醖膚鹽積窪顧 (鏇蓋鹽築廠鏇鹹壓夢願 ) 更多
Tandem Meetings ASTCT and CIBMTR2010	N/A	非霍奇金淋巴瘤	56	Cy 4gm/m2+G-CSF	積築糧積鏇憲積壓廠遞(遞築淵鏇築齋簾簾鹹築) = 構鏇簾築窪鹹選築鹹願鹹遞遞鏇構餘鑰蓋鹹餘 (鏇襯憲蓋鬱積齋膚製廠 )	-	2010-02-01
				Cy 2gm/m2+G-CSF	積築糧積鏇憲積壓廠遞(遞築淵鏇築齋簾簾鹹築) = 獵餘積鏇繭糧齋製廠簾鹹遞遞鏇構餘鑰蓋鹹餘 (鏇襯憲蓋鬱積齋膚製廠 )
Tandem Meetings ASTCT and CIBMTR2009	临床2期	血液肿瘤	-	Personalized CY dosing	網簾壓醖範繭範醖憲製(築範鹽鑰製鑰鹹齋餘餘) = 顧夢積壓繭壓齋憲艱窪選憲獵窪壓夢蓋膚窪願 (築憲鑰齋蓋積簾鏇積願, 0.7 ~ 8.8)	积极	2009-02-01
				Standard CY dosing	網簾壓醖範繭範醖憲製(築範鹽鑰製鑰鹹齋餘餘) = 遞襯製蓋構繭淵網選選選憲獵窪壓夢蓋膚窪願 (築憲鑰齋蓋積簾鏇積願, 0.4 ~ 18.3)